The current state-of-the-art in the treatment of DKD concentrates on optimized glucose control, use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in patients with eGFR ≥ 25 mL/min/1.73 m2 and albuminuria (uACR ≥ 300 mg/g), or mineralocorticoid receptor antagonist finrenon in those not capable of receiving SGLT-2 inhibitors, renin–angiotensin–aldosteron (RAA) blockade in moderately albuminuric patients (uACR 30–299 mg/g) [68]. Here, SLC5A2 is linked to diabetic kidney disease.